Illegal Animal Meds Persist in India

Use of a veterinary painkiller, banned in several countries because of its lethal effects on scavenging birds, has declined, but cow carcasses still test positive.

Written byKerry Grens
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

PHOTO COURTESY: MUNIR VIRANI, THE PEREGRINE FUNDA mass killing of several species of vultures in the Indian subcontinent over the last two decades is largely blamed on the presence of a drug, diclofenac, in the cow carcasses the birds eat. The Indian government banned veterinary use of the painkiller in 2006, and a new study published today (October 13) in Philosophical Transactions of the Royal Society B shows a decline in cow carcasses testing positive for diclofenac and an increase in the use of a vulture-safe alternative drug.

The results are “tremendous news,” Munir Virani, the Africa Programs Director of The Peregrine Fund, a nonprofit dedicated to conserving birds of prey, said in an e-mail to The Scientist. Still, “this does not mean vultures are not dying of diclofenac poisoning,” added Virani, who did not participate in the study. “It simply means that there is much less of it in the environment as shown by this paper and by other ongoing studies.”

Diclofenac is a non-steroidal anti-inflammatory drug (NSAID) that farmers use to ease pain in their cattle. About a decade ago, Rhys Green, a conservation biologist at the Royal Society for the Protection of Birds and the University of Cambridge, and others identified diclofenac as responsible for wiping out vulture populations across ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • kerry grens

    Kerry served as The Scientist’s news director until 2021. Before joining The Scientist in 2013, she was a stringer for Reuters Health, the senior health and science reporter at WHYY in Philadelphia, and the health and science reporter at New Hampshire Public Radio. Kerry got her start in journalism as a AAAS Mass Media fellow at KUNC in Colorado. She has a master’s in biological sciences from Stanford University and a biology degree from Loyola University Chicago.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies